Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
ConclusionsSleep disruption has a high economic burden and reducing itch may provide substantial direct and indirect savings. Quantifying the economic burden of itch-related sleep loss may provide support for analyses to inform public health policies for treatment of atopic dermatitis, particularly within the moderate-to-severe level. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 23, 2024 Category: Dermatology Source Type: research
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
ConclusionThis real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month 6 in the anti-IL-17A cohort compared to the other biologics cohort. Of the individual biologics studied, ixekizumab showed the highest numerical improvements in nail psoriasis at month 12.Trial registrationEUPAS24207. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 22, 2024 Category: Dermatology Source Type: research
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
ConclusionsContinued treatment with ixekizumab provided long-term sustained scalp clearance over 5 years to patients with moderate-to-severe plaque psoriasis and baseline scalp involvement, and holistic improvements occurred across clinical outcomes, patient-reported outcomes, and quality of life.Clinical Trial NumbersNCT01474512 (UNCOVER-1), NCT01597245 (UNCOVER-2), and NCT01646177 (UNCOVER-3). (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 22, 2024 Category: Dermatology Source Type: research
The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995 –2016
ConclusionThis cohort study reported incidence rates and prevalence over time and characteristics of individuals with hospital-treated AA in Denmark, which are in agreement with those previously reported in this population. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 16, 2024 Category: Dermatology Source Type: research
Novel Topical Treatments for Itch
AbstractThe experience of itch often poses a burden on patient quality of life and has the capacity to inflict significant suffering. Topical therapies are a mainstay of treatment for many cutaneous and systemic diseases and afford patients the opportunity to manage their conditions without many of the systemic side effects of non-topical therapies. We review a multitude of new topical medications targeting the skin, immune system, and neural receptors. The list includes Janus kinase inhibitors, tyrosine kinase inhibitors, phosphodiesterase inhibitors, transient receptor vanilloid inhibitors, topical cannabinoids, and topi...
Source: Dermatology and Therapy - April 13, 2024 Category: Dermatology Source Type: research
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
ConclusionThe results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 weeks of therapy. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 13, 2024 Category: Dermatology Source Type: research
Novel Topical Treatments for Itch
AbstractThe experience of itch often poses a burden on patient quality of life and has the capacity to inflict significant suffering. Topical therapies are a mainstay of treatment for many cutaneous and systemic diseases and afford patients the opportunity to manage their conditions without many of the systemic side effects of non-topical therapies. We review a multitude of new topical medications targeting the skin, immune system, and neural receptors. The list includes Janus kinase inhibitors, tyrosine kinase inhibitors, phosphodiesterase inhibitors, transient receptor vanilloid inhibitors, topical cannabinoids, and topi...
Source: Dermatology and Therapy - April 13, 2024 Category: Dermatology Source Type: research
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
ConclusionThe results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 weeks of therapy. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 13, 2024 Category: Dermatology Source Type: research
Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study
ConclusionsOur results highlight that management of AA, in terms of diagnosis and treatment, is still challenging. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 10, 2024 Category: Dermatology Source Type: research
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
AbstractPsoriasis is now considered a systemic disease, and several comorbidities have been described such as cardiovascular diseases, neurologic and psychiatric disorders, chronic inflammatory bowel disease, psoriatic arthritis, etc. Regarding cardiovascular comorbidities, major adverse cardiovascular events have been reported in psoriasis patients by multiple epidemiologic studies. Moreover, smoking, obesity, metabolic syndrome, hypertension, dyslipidemia, diabetes and reduced physical activity are associated with psoriasis, increasing cardiovascular risk. Consequently, several aspects should be considered when making th...
Source: Dermatology and Therapy - April 9, 2024 Category: Dermatology Source Type: research
Letter to the Editor Regarding: Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 9, 2024 Category: Dermatology Source Type: research
Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 9, 2024 Category: Dermatology Source Type: research
Letter to the Editor Regarding: Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 9, 2024 Category: Dermatology Source Type: research
